Dalton Venture Appoints New Member to Deepen Hong Kong Strategic Layout | Advancing to a New Stage of International Investment
As its Hong Kong strategic layout continues to deepen, Dalton Venture is further refining its international investment system. **In July 2026, Mr. Chen Yaochao officially joined Dalton Venture as Managing Director and Head of the Hong Kong Fund. Going forward, he will take full responsibility for the operation, management, and strategic expansion of Dalton Venture's Hong Kong fund**, driving the firm's connectivity to resources in Hong Kong and international capital markets, and further strengthening Dalton Venture's cross-border investment capabilities in life sciences, health, and technology.
Background
As its Hong Kong strategy continues to deepen, Dalton Venture is further building out its international investment infrastructure. In July 2026, Yaochao Chen officially joined Dalton Venture as Managing Director and Head of the Hong Kong Fund. Going forward, he will assume full responsibility for the fund's operations and strategic expansion, strengthening the firm's links to resources in Hong Kong and international capital markets and enhancing Dalton Venture's cross-border investment capabilities in life sciences and technology.
Core Team Upgrade to Accelerate Hong Kong Fund Strategy
Chen brings nearly 20 years of experience in onshore and offshore investment, M&A, and asset management. He holds a bachelor's degree from Southwest Jiaotong University, an MBA from Sun Yat-sen University, and is a CFA charterholder.
Prior to joining Dalton Venture, Chen held positions at CICC Wealth Management, CCB International Direct Investment, China Securities Co., Ltd. International Alternative Investment, and CITIC Bank International Hong Kong Asset Management, progressing through roles including investment associate, assistant vice president, co-director, and department head. He also serves as executive director and chief operating officer of Hong Kong-listed SPAC TechStar (HK.7855), with long-standing expertise in cross-border investment, alternative asset management, and industry funds.
Yaochao Chen, Managing Director and Head of Hong Kong Fund, Dalton Venture
Over the course of his career, Chen was responsible for establishing and managing the CITIC Bank Yuanda Healthcare Fund and the CITIC Bank Asymchem Healthcare Fund, and executed a diverse range of investments and acquisitions including Simcere Pharmaceutical, IASO Biotherapeutics, Broncus Medical, the Sirtex acquisition, the BioVidia acquisition, Zoomlion, CSSC Leasing, China Mobile Indonesia AIDC, Deheng Data Malaysia AIDC, and the TechStar merger with Innovusion (HK.7855) — amassing extensive experience in fund management, industry investment, and cross-border capital operations.
Drawing on years of practice bridging industry, capital, and international markets, Chen has developed a deep understanding of cross-border asset allocation and industry investment logic, with seasoned expertise in fund raising, investment management, resource integration, and capital operations.
Message from the Partners
"Hong Kong is a critical hub connecting global capital, innovative technology, and industrial resources. Yaochao brings years of experience in cross-border asset management, industry funds, and life sciences and technology investment, with a profound understanding of capital market operations, industrial resource integration, and Hong Kong's financial ecosystem. His arrival will further strengthen the Dalton Hong Kong team's capabilities in cross-border investment and resource synergy, advancing the construction of our Hong Kong fund platform and the continuous upgrade of our international resource network. Going forward, we look forward to working with him and the team to leverage Hong Kong's international platform advantages, deepen cooperation with global investment institutions, Hong Kong research organizations, and industry partners, and provide stronger support for Dalton's cross-border deployment in life sciences and technology."
— Qi Sun, Founding Managing Partner, Dalton Venture
Open Collaboration to Build a Life Sciences and Technology Innovation Ecosystem
In April 2026, Dalton Venture Hong Kong Limited, the firm's Hong Kong fund management entity, was selected for the first batch of fund managers under the enhanced Innovation and Technology Venture Fund (ITVF) program of the Hong Kong Special Administrative Region Government's Innovation and Technology Commission.
As the only fund manager in this cohort with a mainland China headquarters in the Yangtze River Delta region, and also the only one focused on the life sciences sector, Dalton Venture's selection reflects the firm's long-term accumulation of vertical industry investment expertise, cross-border resource integration capabilities, and international fund operations infrastructure.
Going forward, the Dalton Hong Kong Fund will center on the "AI + Life Sciences" theme, with a focus on innovation areas featuring high technical barriers and long-term industrial value, including brain science, high-end medical devices (with emphasis on ophthalmology), synthetic biology, and drug discovery.
Yaochao Chen's arrival will further refine the Dalton Hong Kong Fund's operational systems and international resource connectivity, helping the firm link up with more outstanding entrepreneurial teams, industry partners, and global investment institutions.
Investors, entrepreneurial teams, and industry partners are welcome to connect with Dalton Venture to jointly link innovative resources and explore the possibilities of life sciences and technology development.
Dalton Venture Hong Kong Office
📍 Unit 1E209B, Phase 1, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
📞 +852 2553 6789
END
ID: daltonventure
Long press to follow
Recommended Reading
